PUBLISHER: Meticulous Research | PRODUCT CODE: 2132839
PUBLISHER: Meticulous Research | PRODUCT CODE: 2132839
Biologics Fermentation Capacity Market Size, Share, Trends & Forecast Analysis by System Type, Scale of Operation, Mode of Operation, Cell/Organism Type, Application, End User, and Geography - Global Forecast to 2036
The global Biologics Fermentation Capacity Market is estimated at USD 9.85 billion in 2026 and is projected to reach USD 32.40 billion by 2036, expanding at a CAGR of 12.6% during the forecast period. Single-use bioreactor systems account for the largest share of the market in 2026, reflecting their lower capital intensity and faster commissioning timelines, while hybrid facility designs represent the fastest-growing system category with a projected CAGR of 17.9%. The report provides a comprehensive evaluation of the rapidly evolving biologics fermentation capacity market by examining bioprocessing technology innovation, regulatory approval trends, government-backed manufacturing investment, trade and tariff developments, and competitive strategies shaping the biomanufacturing capacity landscape.
Fermentation capacity refers to the installed base of bioreactor and fermenter systems, together with associated upstream processing equipment, used to cultivate mammalian cells, bacteria, yeast, insect cells, and other production organisms for manufacturing biologic drugs. The systems range from bench-top vessels of a few litres used in process development to single-use bioreactors of up to 2,000 to 6,000 litres and stainless-steel bioreactors and microbial fermenters of 15,000 to 25,000 litres used in commercial drug substance production. The category covers classical stainless-steel, reusable bioreactor vessels engineered for large, dedicated commercial production; single-use or disposable bioreactor systems built around pre-sterilized polymer bags that eliminate cleaning and sterilization cycles between batches; and hybrid facility designs that combine both formats within the same production train. A surging biologics pipeline and record regulatory approval volumes, rapid adoption of single-use and modular bioprocessing technology, and government-backed reshoring of domestic biomanufacturing capacity are driving sustained capacity investment across monoclonal antibodies, biosimilars, vaccines, and cell and gene therapy production worldwide.
This report delivers an in-depth assessment of the market by analyzing bioprocessing system innovation, capacity investment trends, policy-driven reshoring initiatives, and competitive positioning shaping industry growth. It evaluates how advancements in single-use platform scale, continuous bioprocessing, hybrid facility configuration, and purpose-built systems for next-generation modalities are reshaping capacity economics. The study also provides strategic market forecasts, segment-level insights, pricing and technology analysis, facility commissioning timelines, and regional analysis across 24 countries and sub-regions to support informed business, investment, and technology decisions.
Market Dynamics
The surging biologics pipeline and record regulatory approvals remain one of the primary drivers of the biologics fermentation capacity market. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research approved 50 novel drugs in 2024, including 16 biologics and 13 monoclonal antibodies-the highest number of antibody approvals since 2015-followed by 46 novel drugs in 2025. Each newly approved biologic requires dedicated or shared fermentation capacity for process development, clinical supply, and commercial launch, creating a direct structural driver of new bioreactor and fermenter installations across CDMOs and in-house manufacturers alike. Rapid adoption of single-use and modular bioprocessing technology, which allows manufacturers to add capacity in months rather than the years typically required for stainless-steel facility construction and needs an estimated 25% to 45% less capital than equivalent stainless-steel facilities, is further accelerating capacity growth.
Government-backed reshoring and public-private investment in domestic biomanufacturing is reshaping the competitive landscape. Governments across major markets are treating biologics manufacturing capacity as a matter of supply security, channeling public-private investment into manufacturing technology and workforce readiness, fast-tracking permitting, and structuring dedicated incentive schemes for fermentation-based production. In the United States, the National Institute for Innovation in Manufacturing Biopharmaceuticals had built a portfolio of 230 projects worth more than USD 216 million by May 2026, while a Section 232 proclamation of April 2026 imposing a 100% tariff on imported patented pharmaceuticals, with lower rates for companies holding approved onshoring plans, has sharpened the commercial case for domestic capacity. In Europe, the proposed Critical Medicines Act and European Biotech Act are designed to accelerate permitting and provide targeted financial support for EU-based biomanufacturing, and India's production-linked incentive frameworks specifically target fermentation-based products. This policy support is reinforcing a broader shift toward hybrid facility designs that combine single-use flexibility with stainless-steel scale, alongside rising adoption of continuous bioprocessing and process intensification-supported by the ICH Q13 guideline on continuous manufacturing-to extract more output from existing fermentation footprints.
Despite favorable market conditions, several challenges continue to influence industry adoption. High capital intensity and long gestation periods for capacity buildout, stemming from the inherently slower and less predictable growth cycles of living cells compared with chemical synthesis, remain an important constraint, and equipment demand proved cyclical as biopharmaceutical companies and CDMOs reduced capital spending between 2023 and 2025 following the build-out of pandemic-era capacity. A shortage of skilled bioprocessing workforce and engineering talent also limits how quickly newly commissioned bioreactor capacity can be adequately staffed, validated, and utilized, tempering the pace at which nominal capacity additions translate into commercial output.
The market nevertheless presents substantial long-term opportunities. The expansion of fermentation capacity for cell and gene therapy and other next-generation modalities requiring purpose-built platforms distinct from those optimized for monoclonal antibodies, and the localization of biomanufacturing capacity in emerging markets through nationally supported programs, are expected to create favorable conditions for future market growth. As the biologics pipeline continues to expand and policy support for domestic manufacturing strengthens, demand for fermentation capacity is expected to increase significantly across both developed and emerging markets.
Segment Analysis
The report provides detailed market analysis across system type, scale of operation, mode of operation, cell/organism type, application, end user, and geography, enabling stakeholders to identify high-growth business opportunities and evolving biomanufacturing trends.
Based on system type, the market is segmented into single-use (disposable) bioreactor systems, stainless steel (reusable) bioreactor systems, and hybrid systems. In 2026, the single-use (disposable) bioreactor systems segment is expected to account for the largest share of the global market. The largest share of this segment is supported by the use of single-use bioreactors in process development, clinical manufacturing, and multi-product commercial facilities, along with lower upfront capital requirements and faster facility commissioning timelines. However, the hybrid systems segment is slated to register the highest growth, as large commercial manufacturers pursue blended capacity strategies pairing single-use seed and clinical bioreactors with stainless-steel production bioreactors.
Based on scale of operation, the commercial/large scale segment is expected to account for the largest share of the global market in 2026, reflecting the high value of multi-thousand-litre production bioreactors and fermenters and the scale of CDMO and drug manufacturer capacity expansions. The bench & pilot scale segment is projected to register the highest growth, driven by the number of programmes in development, the replacement of glass bioreactors with single-use and multi-parallel systems, and bench systems that scale directly to production.
Based on mode of operation, the fed-batch segment is expected to account for the largest share of the global market in 2026, as fed-batch culture remains the standard production process for monoclonal antibodies and biosimilars. The perfusion/continuous segment is slated to register the highest growth, driven by process intensification, the ICH Q13 guideline on continuous manufacturing, and bioreactors purpose-designed for perfusion operation.
Based on cell/organism type, the mammalian cell culture segment is expected to account for the largest share of the global market in 2026, attributed to the production of antibodies, biosimilars, and other glycosylated proteins in Chinese hamster ovary cells. The microbial fermentation segment is projected to register the highest growth, supported by peptides, antibody fragments, enzymes, and plasmid DNA, new microbial capacity additions, and incentives for fermentation-based products in India.
Based on application, the monoclonal antibodies & biosimilars segment is expected to account for the largest share of the global market in 2026, reflecting record antibody and biosimilar approval volumes. The cell & gene therapy segment is slated to register the highest growth, driven by approvals of cell and gene therapies, the movement of viral vector and cell therapy programmes into commercial production, and purpose-built bioreactor platforms for these modalities.
Based on end user, the CDMOs/CMOs segment is expected to account for the largest share of the global market in 2026, supported by large capacity expansions among contract manufacturers in the United States, Europe, and Asia and by continued outsourcing from biotechnology companies. The biopharmaceutical & biotechnology companies segment is projected to register the highest growth, driven by manufacturing investment commitments announced by drug manufacturers and government programmes supporting domestic biomanufacturing.
Regional Analysis
The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, covering 24 countries and sub-regions. Regional evaluations consider regulatory approval density, CDMO network scale, trade and tariff measures, and government manufacturing incentive programs influencing market growth.
In 2026, North America is expected to account for the largest share of the global biologics fermentation capacity market. The region's leading position is attributed to the concentration of biopharmaceutical companies, biotechnology developers, and CDMOs in the United States, the volume of biologics approved by the FDA, the manufacturing investments announced following the Section 232 investigation into pharmaceutical imports, and public funding channeled through federal manufacturing technology programs. Europe anchored by large single-site expansions in Denmark, Switzerland, Germany, and Ireland, and by proposed legislation designed to fast-track permitting and provide targeted financial support for EU-based biomanufacturing capacity.
Asia-Pacific is expected to register the fastest growth throughout the forecast period. This growth is driven by large-scale capacity build-out in China, continued expansion of South Korea's contract manufacturing base in Songdo, national incentive schemes specifically targeting fermentation-based production in India, and dual-use biopharmaceutical manufacturing programmes in Japan. Latin America and the Middle East & Africa remain earlier-stage markets, with growth concentrated in national health security and import-substitution initiatives for essential biologics, vaccines, and fermentation-based drugs.
Competitive Landscape
The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their platform innovation, capacity expansion investments, acquisitions, geographic diversification, and recent business developments.
In 2025, the global biologics fermentation capacity market was moderately consolidated, with the top five players collectively accounting for a share of 41.5% of the market and the remainder shared among specialist bench and pilot suppliers, engineering companies supplying custom stainless-steel systems, and regional manufacturers. Competitive benchmarking enables stakeholders to evaluate companies based on system type coverage across single-use, stainless-steel, and hybrid formats, scale range, facility footprint, registered geographies, and capacity investment scale. Between January 2025 and September 2026, the profiled companies extended their bioreactor ranges across scales and modalities-including 500-litre and 2,000-litre additions to Cytiva's Xcellerex X-platform, Thermo Fisher Scientific's 5-litre DynaDrive single-use bioreactor, and ABEC's Advanced Therapy Bioreactor-and pursued acquisitions and capacity investments such as Thermo Fisher Scientific's USD 4.0 billion acquisition of Solventum's Purification and Filtration business and Cytiva's USD 1.6 billion capacity investment programme. The study also analyzes how established bioprocess equipment manufacturers with global service networks compete alongside specialist single-use, modular, and advanced therapy system providers within this evolving biomanufacturing capacity landscape.
Key companies profiled in the report include Sartorius AG (Germany), Danaher Corporation/Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Eppendorf SE (Germany), ABEC, Inc. (U.S.), Getinge AB (Sweden), Tofflon Science and Technology Group Co., Ltd. (China), GEA Group Aktiengesellschaft (Germany), Pierre Guerin (France), ZETA GmbH (Austria), Bioengineering AG (Switzerland), INFORS HT (Switzerland), PBS Biotech, Inc. (U.S.), bbi-biotech GmbH (Germany), and Solaris Biotechnology S.r.l. (Italy).
How This Report Helps
- Provides accurate market size estimates and long-term forecasts for the global biologics fermentation capacity market.
- Evaluates the impact of bioprocessing technology innovation, regulatory approval trends, trade measures, and government manufacturing investment on market growth.
- Identifies high-growth opportunities across system types, scales of operation, modes of operation, cell/organism types, applications, end users, and geographic regions.
- Analyzes capacity investment trends, policy-driven reshoring initiatives, facility commissioning timelines, and workforce development shaping market growth.
- Benchmarks leading companies based on platform capability, scale range, facility footprint, and competitive positioning.
- Supports product development, investment planning, partnership evaluation, market entry, and business expansion strategies.
- Delivers actionable market intelligence for bioprocess equipment manufacturers, CDMOs, biopharmaceutical companies, investors, and biomanufacturing organizations.
Key Questions Answered
- What is the current size of the global biologics fermentation capacity market, and how is it expected to evolve through 2036?
- Which technological, regulatory, and policy factors are driving market growth?
- What are the major drivers, restraints, opportunities, and challenges influencing industry development?
- Which system type, scale of operation, mode of operation, cell/organism type, application, end-user, and regional segments are expected to experience the strongest growth?
- How do single-use, stainless-steel, and hybrid facility configurations compare on capital and operating cost, and how is this shaping capacity investment decisions?
- Which geographic markets present the most attractive business opportunities?
- Who are the leading companies operating in the market, and what competitive strategies are they adopting?
- What recent platform launches, capacity investments, acquisitions, and policy developments are shaping the competitive landscape?
- How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, and long-term business strategy?
TABLE OF CONTENTS
- Table of Contents
1. Introduction
- 1.1. Market Definition
- 1.2. Currency & Limitations
- 1.2.1. Currency
- 1.2.2. Limitations
2. Research Methodology
- 2.1. Research Approach
- 2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
- 2.3. Market Assessment
- 2.3.1. Market Size Estimation
- 2.3.2. Bottom-Up Approach
- 2.3.3. Top-Down Approach
- 2.3.4. Growth Forecast
- 2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
- 4.1. Overview
- 4.2. Factors Affecting Market Growth
- 4.2.1. Drivers
- 4.2.1.1. Surging Biologics Pipeline and Record Regulatory Approvals
- 4.2.1.2. Rapid Adoption of Single-Use and Modular Bioprocessing Technology
- 4.2.1.3. Government-Backed Reshoring and Public-Private Investment in Domestic Biomanufacturing
- 4.2.2. Restraints
- 4.2.2.1. High Capital Intensity and Long Gestation Periods for Capacity Buildout
- 4.2.3. Opportunities
- 4.2.3.1. Expansion of Fermentation Capacity for Cell and Gene Therapy and Next-Generation Modalities
- 4.2.3.2. Localization of Biomanufacturing Capacity in Emerging Markets
- 4.2.4. Challenges
- 4.2.4.1. Shortage of Skilled Bioprocessing Workforce and Engineering Talent Expected to Remain a Major Challenge
- 4.2.1. Drivers
- 4.3. Key Trends
- 4.3.1. Shift Toward Hybrid Facility Designs Combining Single-Use Flexibility with Stainless-Steel Scale
- 4.3.2. Rise of Continuous Bioprocessing and Process Intensification
- 4.4. Vendor Selection Criteria/Factors Influencing Purchase Decisions
- 4.5. Use Cases
- 4.6. Porter's Five Forces Analysis
- 4.6.1. Bargaining Power of Buyers: Moderate
- 4.6.2. Bargaining Power of Suppliers: Moderate to High
- 4.6.3. Threat of Substitutes: Low to Moderate
- 4.6.4. Threat of New Entrants: Moderate
- 4.6.5. Degree of Competition: High
- 4.7. Value Chain Analysis
- 4.8. Pricing Analysis (Single-Use vs. Stainless-Steel Capital and Operating Cost Comparison)
- 4.9. Technology Analysis (Traditional Stirred-Tank vs. Single-Use, Vertical-Wheel, and Advanced Therapy Bioreactor Platforms)
- 4.10. Facility Design and Commissioning Timeline Analysis
- 4.11. Regulatory Landscape (U.S. FDA/CBER, EU Critical Medicines Act & European Biotech Act, India Fertilizer & Pharmaceutical PLI Frameworks, Other National Biomanufacturing Programmes)
- 4.12. Government Subsidy and Incentive Landscape
- 4.13. PESTEL Analysis
5. Biologics Fermentation Capacity Market Assessment, by System Type
- 5.1. Overview
- 5.2. Single-Use (Disposable) Bioreactor Systems
- 5.3. Stainless Steel (Reusable) Bioreactor Systems
- 5.4. Hybrid Systems
6. Biologics Fermentation Capacity Market Assessment, by Scale of Operation
- 6.1. Overview
- 6.2. Bench & Pilot Scale
- 6.3. Clinical Scale
- 6.4. Commercial/Large Scale
7. Biologics Fermentation Capacity Market Assessment, by Mode of Operation
- 7.1. Overview
- 7.2. Batch
- 7.3. Fed-Batch
- 7.4. Perfusion/Continuous
8. Biologics Fermentation Capacity Market Assessment, by Cell/Organism Type
- 8.1. Overview
- 8.2. Mammalian Cell Culture
- 8.3. Microbial Fermentation
- 8.4. Others (Insect Cell, Yeast & Alternative Platforms)
9. Biologics Fermentation Capacity Market Assessment, by Application
- 9.1. Overview
- 9.2. Monoclonal Antibodies & Biosimilars
- 9.3. Vaccines
- 9.4. Cell & Gene Therapy
- 9.5. Recombinant Proteins & Enzymes
10. Biologics Fermentation Capacity Market Assessment, by End User
- 10.1. Overview
- 10.2. CDMOs/CMOs
- 10.3. Biopharmaceutical & Biotechnology Companies
- 10.4. Academic & Research Institutes
11. Biologics Fermentation Capacity Market Assessment, by Geography
- 11.1. Overview
- 11.2. North America
- 11.2.1. United States
- 11.2.2. Canada
- 11.3. Europe
- 11.3.1. Germany
- 11.3.2. United Kingdom
- 11.3.3. France
- 11.3.4. Denmark
- 11.3.5. Switzerland
- 11.3.6. Italy
- 11.3.7. Rest of Europe
- 11.4. Asia-Pacific
- 11.4.1. China
- 11.4.2. South Korea
- 11.4.3. India
- 11.4.4. Japan
- 11.4.5. Australia & New Zealand
- 11.4.6. Rest of Asia-Pacific
- 11.5. Latin America
- 11.5.1. Brazil
- 11.5.2. Argentina
- 11.5.3. Mexico
- 11.5.4. Rest of Latin America
- 11.6. Middle East & Africa
- 11.6.1. Saudi Arabia
- 11.6.2. United Arab Emirates
- 11.6.3. South Africa
- 11.6.4. Rest of Middle East & Africa
12. Competitive Landscape
- 12.1. Introduction
- 12.2. Key Growth Strategies
- 12.3. Competitive Benchmarking (System Type Coverage, Scale Range, Facility Footprint, Registered Geographies)
- 12.4. Competitive Dashboard
- 12.4.1. Industry Leaders
- 12.4.2. Market Differentiators
- 12.4.3. Vanguards
- 12.4.4. Emerging Companies
- 12.5. Market Share/Position Analysis
13. Company Profiles
- 13.1. Sartorius AG
- 13.1.1. Business Overview
- 13.1.2. Financial Overview
- 13.1.3. Product Portfolio
- 13.1.4. SWOT Analysis
- 13.1.5. Strategic Developments
- 13.2. Danaher Corporation/Cytiva
- 13.2.1. Business Overview
- 13.2.2. Financial Overview
- 13.2.3. Product Portfolio
- 13.2.4. SWOT Analysis
- 13.2.5. Strategic Developments
- 13.3. Thermo Fisher Scientific Inc.
- 13.3.1. Business Overview
- 13.3.2. Financial Overview
- 13.3.3. Product Portfolio
- 13.3.4. SWOT Analysis
- 13.3.5. Strategic Developments
- 13.4. Merck KGaA
- 13.4.1. Business Overview
- 13.4.2. Financial Overview
- 13.4.3. Product Portfolio
- 13.4.4. SWOT Analysis
- 13.4.5. Strategic Developments
- 13.5. Eppendorf SE
- 13.5.1. Business Overview
- 13.5.2. Financial Overview
- 13.5.3. Product Portfolio
- 13.5.4. SWOT Analysis
- 13.5.5. Strategic Developments
- 13.6. ABEC, Inc.
- 13.6.1. Business Overview
- 13.6.2. Product Portfolio
- 13.6.3. SWOT Analysis
- 13.6.4. Strategic Developments
- 13.7. Getinge AB
- 13.7.1. Business Overview
- 13.7.2. Financial Overview
- 13.7.3. Product Portfolio
- 13.7.4. SWOT Analysis
- 13.7.5. Strategic Developments
- 13.8. Tofflon Science and Technology Group Co., Ltd.
- 13.8.1. Business Overview
- 13.8.2. Financial Overview
- 13.8.3. Product Portfolio
- 13.8.4. SWOT Analysis
- 13.8.5. Strategic Developments
- 13.9. GEA Group Aktiengesellschaft
- 13.9.1. Business Overview
- 13.9.2. Financial Overview
- 13.9.3. Product Portfolio
- 13.9.4. SWOT Analysis
- 13.9.5. Strategic Developments
- 13.10. Pierre Guerin
- 13.10.1. Business Overview
- 13.10.2. Product Portfolio
- 13.10.3. SWOT Analysis
- 13.10.4. Strategic Developments
- 13.11. ZETA GmbH
- 13.11.1. Business Overview
- 13.11.2. Product Portfolio
- 13.11.3. SWOT Analysis
- 13.12. Bioengineering AG
- 13.12.1. Business Overview
- 13.12.2. Product Portfolio
- 13.12.3. SWOT Analysis
- 13.13. INFORS HT
- 13.13.1. Business Overview
- 13.13.2. Product Portfolio
- 13.13.3. SWOT Analysis
- 13.14. PBS Biotech, Inc.
- 13.14.1. Business Overview
- 13.14.2. Product Portfolio
- 13.14.3. SWOT Analysis
- 13.14.4. Strategic Developments
- 13.15. bbi-biotech GmbH
- 13.15.1. Business Overview
- 13.15.2. Product Portfolio
- 13.15.3. SWOT Analysis
- 13.16. Solaris Biotechnology S.r.l. (Donaldson Company, Inc.)
- 13.16.1. Business Overview
- 13.16.2. Financial Overview
- 13.16.3. Product Portfolio
- 13.16.4. SWOT Analysis
- 13.16.5. Strategic Developments
14. Appendix
- 14.1. Available Customization
- 14.2. Related Reports
LIST OF TABLES
List of Tables
- Table 1. Currency Conversion Rates Used in This Study
- Table 2. Global Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 3. Global Single-Use (Disposable) Bioreactor Systems Market, by Country/Region, 2024-2036 (USD Million)
- Table 4. Global Stainless Steel (Reusable) Bioreactor Systems Market, by Country/Region, 2024-2036 (USD Million)
- Table 5. Global Hybrid Systems Market, by Country/Region, 2024-2036 (USD Million)
- Table 6. Global Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 7. Global Bench & Pilot Scale Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 8. Global Clinical Scale Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 9. Global Commercial/Large Scale Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 10. Global Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 11. Global Batch Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 12. Global Fed-Batch Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 13. Global Perfusion/Continuous Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 14. Global Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 15. Global Mammalian Cell Culture Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 16. Global Microbial Fermentation Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 17. Global Others (Insect Cell, Yeast & Alternative Platforms) Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 18. Global Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 19. Global Monoclonal Antibodies & Biosimilars Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 20. Global Vaccines Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 21. Global Cell & Gene Therapy Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 22. Global Recombinant Proteins & Enzymes Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 23. Global Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 24. Global CDMOs/CMOs Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 25. Global Biopharmaceutical & Biotechnology Companies Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 26. Global Academic & Research Institutes Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 27. Global Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Table 28. North America: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Table 29. North America: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 30. North America: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 31. North America: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 32. North America: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 33. North America: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 34. North America: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 35. U.S.: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 36. U.S.: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 37. U.S.: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 38. U.S.: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 39. U.S.: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 40. U.S.: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 41. Canada: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 42. Canada: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 43. Canada: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 44. Canada: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 45. Canada: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 46. Canada: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 47. Europe: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Table 48. Europe: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 49. Europe: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 50. Europe: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 51. Europe: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 52. Europe: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 53. Europe: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 54. Germany: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 55. Germany: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 56. Germany: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 57. Germany: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 58. Germany: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 59. Germany: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 60. U.K.: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 61. U.K.: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 62. U.K.: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 63. U.K.: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 64. U.K.: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 65. U.K.: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 66. France: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 67. France: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 68. France: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 69. France: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 70. France: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 71. France: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 72. Denmark: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 73. Denmark: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 74. Denmark: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 75. Denmark: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 76. Denmark: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 77. Denmark: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 78. Switzerland: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 79. Switzerland: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 80. Switzerland: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 81. Switzerland: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 82. Switzerland: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 83. Switzerland: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 84. Italy: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 85. Italy: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 86. Italy: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 87. Italy: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 88. Italy: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 89. Italy: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 90. Rest of Europe: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 91. Rest of Europe: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 92. Rest of Europe: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 93. Rest of Europe: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 94. Rest of Europe: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 95. Rest of Europe: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 96. Asia-Pacific: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Table 97. Asia-Pacific: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 98. Asia-Pacific: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 99. Asia-Pacific: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 100. Asia-Pacific: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 101. Asia-Pacific: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 102. Asia-Pacific: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 103. China: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 104. China: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 105. China: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 106. China: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 107. China: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 108. China: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 109. South Korea: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 110. South Korea: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 111. South Korea: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 112. South Korea: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 113. South Korea: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 114. South Korea: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 115. India: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 116. India: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 117. India: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 118. India: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 119. India: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 120. India: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 121. Japan: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 122. Japan: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 123. Japan: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 124. Japan: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 125. Japan: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 126. Japan: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 127. Australia & New Zealand: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 128. Australia & New Zealand: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 129. Australia & New Zealand: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 130. Australia & New Zealand: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 131. Australia & New Zealand: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 132. Australia & New Zealand: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 133. Rest of Asia-Pacific: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 134. Rest of Asia-Pacific: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 135. Rest of Asia-Pacific: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 136. Rest of Asia-Pacific: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 137. Rest of Asia-Pacific: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 138. Rest of Asia-Pacific: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 139. Latin America: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Table 140. Latin America: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 141. Latin America: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 142. Latin America: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 143. Latin America: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 144. Latin America: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 145. Latin America: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 146. Brazil: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 147. Brazil: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 148. Brazil: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 149. Brazil: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 150. Brazil: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 151. Brazil: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 152. Argentina: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 153. Argentina: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 154. Argentina: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 155. Argentina: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 156. Argentina: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 157. Argentina: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 158. Mexico: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 159. Mexico: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 160. Mexico: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 161. Mexico: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 162. Mexico: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 163. Mexico: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 164. Rest of Latin America: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 165. Rest of Latin America: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 166. Rest of Latin America: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 167. Rest of Latin America: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 168. Rest of Latin America: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 169. Rest of Latin America: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 170. Middle East & Africa: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Table 171. Middle East & Africa: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 172. Middle East & Africa: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 173. Middle East & Africa: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 174. Middle East & Africa: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 175. Middle East & Africa: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 176. Middle East & Africa: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 177. Saudi Arabia: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 178. Saudi Arabia: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 179. Saudi Arabia: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 180. Saudi Arabia: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 181. Saudi Arabia: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 182. Saudi Arabia: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 183. UAE: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 184. UAE: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 185. UAE: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 186. UAE: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 187. UAE: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 188. UAE: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 189. South Africa: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 190. South Africa: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 191. South Africa: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 192. South Africa: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 193. South Africa: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 194. South Africa: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 195. Rest of Middle East & Africa: Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Table 196. Rest of Middle East & Africa: Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Table 197. Rest of Middle East & Africa: Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Table 198. Rest of Middle East & Africa: Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Table 199. Rest of Middle East & Africa: Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Table 200. Rest of Middle East & Africa: Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Table 201. Sartorius AG: Product Portfolio
- Table 202. Danaher Corporation/Cytiva: Product Portfolio
- Table 203. Thermo Fisher Scientific Inc.: Product Portfolio
- Table 204. Merck KGaA: Product Portfolio
- Table 205. Eppendorf SE: Product Portfolio
- Table 206. ABEC, Inc.: Product Portfolio
- Table 207. Getinge AB: Product Portfolio
- Table 208. Tofflon Science and Technology Group Co., Ltd.: Product Portfolio
- Table 209. GEA Group Aktiengesellschaft: Product Portfolio
- Table 210. Pierre Guerin: Product Portfolio
- Table 211. ZETA GmbH: Product Portfolio
- Table 212. Bioengineering AG: Product Portfolio
- Table 213. INFORS HT: Product Portfolio
- Table 214. PBS Biotech, Inc.: Product Portfolio
- Table 215. bbi-biotech GmbH: Product Portfolio
- Table 216. Solaris Biotechnology S.r.l.: Product Portfolio
LIST OF FIGURES
List of Figures
- Figure 1. Biologics Fermentation Capacity Market, Segmentation and Scope
- Figure 2. Research Process
- Figure 3. Secondary Sources Referenced for This Study
- Figure 4. Primary Research Techniques
- Figure 5. Key Executives Interviewed
- Figure 6. Breakdown of Primary Interviews (Supply-Side and Demand-Side, by Region)
- Figure 7. Market Sizing and Growth Forecast Approach
- Figure 8. Executive Summary: Global Biologics Fermentation Capacity Market, by System Type, 2026 Vs. 2036 (USD Million)
- Figure 9. Executive Summary: Global Biologics Fermentation Capacity Market, by Scale of Operation, 2026 Vs. 2036 (USD Million)
- Figure 10. Executive Summary: Global Biologics Fermentation Capacity Market, by Mode of Operation, 2026 Vs. 2036 (USD Million)
- Figure 11. Executive Summary: Global Biologics Fermentation Capacity Market, by Cell/Organism Type, 2026 Vs. 2036 (USD Million)
- Figure 12. Executive Summary: Global Biologics Fermentation Capacity Market, by Application, 2026 Vs. 2036 (USD Million)
- Figure 13. Executive Summary: Global Biologics Fermentation Capacity Market, by End User, 2026 Vs. 2036 (USD Million)
- Figure 14. Global Biologics Fermentation Capacity Market, by Geography
- Figure 15. Biologics Fermentation Capacity Market: Competitive Dashboard
- Figure 16. Evolution of Bioreactor and Fermenter Technology for Biologics Manufacturing
- Figure 17. Biologics Fermentation Capacity Market, Factors Affecting Market Growth
- Figure 18. FDA Novel Drug Approvals and Biologics, 2023-2025
- Figure 19. Single-Use Bioreactor Platforms and Working Volumes, by Supplier
- Figure 20. Announced U.S. Manufacturing Investment Commitments by Drug Manufacturers, 2025
- Figure 21. Capital Investment in Large-Scale Biologics Capacity Projects
- Figure 22. Bioreactor Platforms for Cell and Gene Therapy and Next-Generation Modalities
- Figure 23. Emerging-Market Biomanufacturing Capacity Projects
- Figure 24. Workforce Requirements for New Biomanufacturing Capacity
- Figure 25. Hybrid Facility Design: Single-Use and Stainless-Steel Equipment in One Production Train
- Figure 26. Fed-Batch, Intensified Fed-Batch and Perfusion Processes
- Figure 27. Key Vendor Selection Criteria
- Figure 28. Use Cases for Bioreactor and Fermenter Systems
- Figure 29. Porter's Five Forces Analysis
- Figure 30. Biologics Fermentation Capacity Market, Value Chain Analysis
- Figure 31. Single-Use Vs. Stainless-Steel: Capital and Operating Cost Comparison
- Figure 32. Bioreactor Platform Technologies: Stirred-Tank, Single-Use, Vertical-Wheel and Advanced Therapy Systems
- Figure 33. Facility Design and Commissioning Timeline: Stainless-Steel Vs. Single-Use and Modular Facilities
- Figure 34. Regulatory Frameworks Affecting Biologics Fermentation Capacity
- Figure 35. Government Programmes Supporting Biomanufacturing Capacity
- Figure 36. PESTEL Analysis of the Biologics Fermentation Capacity Market
- Figure 37. Bioreactor System Types: Single-Use, Stainless Steel and Hybrid
- Figure 38. Global Biologics Fermentation Capacity Market, by System Type, 2026 Vs. 2036 (USD Million)
- Figure 39. Global Biologics Fermentation Capacity Market, by System Type, 2024-2036 (USD Million)
- Figure 40. Single-Use Bioreactor Platforms and Maximum Working Volumes, by Supplier
- Figure 41. Global Single-Use (Disposable) Bioreactor Systems Market, by Country/Region, 2024-2036 (USD Million)
- Figure 42. Large-Scale Stainless-Steel Bioreactor Capacity, by Site
- Figure 43. Global Stainless Steel (Reusable) Bioreactor Systems Market, by Country/Region, 2024-2036 (USD Million)
- Figure 44. Hybrid Production Train: Single-Use Seed Bioreactors and Stainless-Steel Production Bioreactors
- Figure 45. Global Hybrid Systems Market, by Country/Region, 2024-2036 (USD Million)
- Figure 46. Bioreactor Scales from Process Development to Commercial Production
- Figure 47. Global Biologics Fermentation Capacity Market, by Scale of Operation, 2026 Vs. 2036 (USD Million)
- Figure 48. Global Biologics Fermentation Capacity Market, by Scale of Operation, 2024-2036 (USD Million)
- Figure 49. Bench and Pilot Bioreactor Systems: Formats and Uses
- Figure 50. Global Bench & Pilot Scale Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 51. Clinical Manufacturing with Single-Use Bioreactors
- Figure 52. Global Clinical Scale Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 53. Commercial-Scale Capacity Projects, by Company and Site
- Figure 54. Global Commercial/Large Scale Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 55. Batch, Fed-Batch and Perfusion Processes: Feeding, Harvest and Cell Density
- Figure 56. Global Biologics Fermentation Capacity Market, by Mode of Operation, 2026 Vs. 2036 (USD Million)
- Figure 57. Global Biologics Fermentation Capacity Market, by Mode of Operation, 2024-2036 (USD Million)
- Figure 58. Batch Operation in Seed Trains, Vaccines and Microbial Fermentation
- Figure 59. Global Batch Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 60. Fed-Batch Production in Stainless-Steel and Single-Use Bioreactors
- Figure 61. Global Fed-Batch Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 62. Perfusion Bioreactor with Cell Retention and Continuous Harvest
- Figure 63. Global Perfusion/Continuous Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 64. Expression Platforms for Biologics: Mammalian, Microbial, Yeast and Insect Cells
- Figure 65. Global Biologics Fermentation Capacity Market, by Cell/Organism Type, 2026 Vs. 2036 (USD Million)
- Figure 66. Global Biologics Fermentation Capacity Market, by Cell/Organism Type, 2024-2036 (USD Million)
- Figure 67. Mammalian Bioreactor Capacity: Antibodies, Biosimilars and Viral Vectors
- Figure 68. Global Mammalian Cell Culture Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 69. Microbial Fermentation: Products, Fermenter Requirements and Capacity Projects
- Figure 70. Global Microbial Fermentation Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 71. Yeast, Insect Cell and Alternative Expression Platforms: Products and Bioreactor Requirements
- Figure 72. Global Others (Insect Cell, Yeast & Alternative Platforms) Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 73. Bioreactor Requirements by Application: Antibodies, Vaccines, Cell and Gene Therapy and Recombinant Proteins
- Figure 74. Global Biologics Fermentation Capacity Market, by Application, 2026 Vs. 2036 (USD Million)
- Figure 75. Global Biologics Fermentation Capacity Market, by Application, 2024-2036 (USD Million)
- Figure 76. Antibody and Biosimilar Manufacturing Capacity, by Site
- Figure 77. Global Monoclonal Antibodies & Biosimilars Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 78. Vaccine Production Platforms and Bioreactor Types
- Figure 79. Global Vaccines Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 80. Cell and Gene Therapy Manufacturing: Cell Expansion and Viral Vector Bioreactors
- Figure 81. Global Cell & Gene Therapy Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 82. Recombinant Protein and Enzyme Production by Platform
- Figure 83. Global Recombinant Proteins & Enzymes Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 84. End Users of Bioreactor and Fermenter Systems and Their Purchasing Patterns
- Figure 85. Global Biologics Fermentation Capacity Market, by End User, 2026 Vs. 2036 (USD Million)
- Figure 86. Global Biologics Fermentation Capacity Market, by End User, 2024-2036 (USD Million)
- Figure 87. CDMO Capacity Expansions, by Company and Site
- Figure 88. Global CDMOs/CMOs Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 89. Drug Manufacturer Biomanufacturing Investments, 2023-2026
- Figure 90. Global Biopharmaceutical & Biotechnology Companies Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 91. Bioreactor Use in Academic Research, Training and Translational Manufacturing
- Figure 92. Global Academic & Research Institutes Biologics Fermentation Capacity Market, by Country/Region, 2024-2036 (USD Million)
- Figure 93. Global Biologics Fermentation Capacity Market, by Geography, 2026 Vs. 2036 (USD Million)
- Figure 94. Global Biologics Fermentation Capacity Market, by Geography, 2024-2036 (USD Million)
- Figure 95. Global Biologics Fermentation Capacity Market: Geographic Snapshot
- Figure 96. North America: Biologics Fermentation Capacity Market Snapshot
- Figure 97. North America: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Figure 98. U.S. Biomanufacturing Investment Commitments and Capacity Projects, 2024-2026
- Figure 99. Canada: Biomanufacturing and Life Sciences Strategy Projects
- Figure 100. Europe: Biologics Fermentation Capacity Market Snapshot
- Figure 101. Europe: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Figure 102. Germany: Biopharmaceutical Manufacturing Sites and Bioreactor Suppliers
- Figure 103. U.K.: Biomanufacturing Investments and Vaccine Partnerships
- Figure 104. France: Sanofi Bioproduction Investments
- Figure 105. Denmark: Hillerod and Kalundborg Capacity Expansions
- Figure 106. Switzerland: Large-Scale Biologics Sites and Bioreactor Suppliers
- Figure 107. Italy: Pharmaceutical Production, Exports and Investment, 2025
- Figure 108. Rest of Europe: Biologics Manufacturing Sites
- Figure 109. Asia-Pacific: Biologics Fermentation Capacity Market Snapshot
- Figure 110. Asia-Pacific: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Figure 111. China: Innovative Drug Approvals and Out-Licensing, 2024-2025
- Figure 112. South Korea: Songdo Biologics Capacity, by Company
- Figure 113. India: Government Programmes Supporting Fermentation and Biomanufacturing
- Figure 114. Japan: METI Dual-Use Biopharmaceutical Manufacturing Projects
- Figure 115. Australia: Sovereign Vaccine Manufacturing Facilities
- Figure 116. Rest of Asia-Pacific: Biologics Manufacturing Hubs
- Figure 117. Latin America: Biologics Fermentation Capacity Market Snapshot
- Figure 118. Latin America: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Figure 119. Brazil: Public Vaccine and Biologics Production Projects
- Figure 120. Argentina: Biosimilar and Vaccine Manufacturing
- Figure 121. Mexico: Biologics and Vaccine Manufacturing Initiatives
- Figure 122. Rest of Latin America: Biomanufacturing Initiatives
- Figure 123. Middle East & Africa: Biologics Fermentation Capacity Market Snapshot
- Figure 124. Middle East & Africa: Biologics Fermentation Capacity Market, by Country, 2024-2036 (USD Million)
- Figure 125. Saudi Arabia: National Biotechnology Strategy and Biomanufacturing Projects
- Figure 126. United Arab Emirates: Biomanufacturing Facilities and Investors
- Figure 127. South Africa: Vaccine Manufacturing Expansion
- Figure 128. Rest of Middle East & Africa: Vaccine and Biologics Manufacturing Projects
- Figure 129. Biologics Fermentation Capacity Market: Competitive Structure
- Figure 130. Key Growth Strategies Adopted by Leading Market Players, 2025-2026
- Figure 131. Strategic Developments, by Company, 2025-2026
- Figure 132. Biologics Fermentation Capacity Market: Competitive Benchmarking, by System Type Coverage
- Figure 133. Biologics Fermentation Capacity Market: Competitive Benchmarking, by Scale Range
- Figure 134. Biologics Fermentation Capacity Market: Competitive Benchmarking, by Facility Footprint
- Figure 135. Biologics Fermentation Capacity Market: Competitive Benchmarking, by Registered Geographies
- Figure 136. Competitive Dashboard: Biologics Fermentation Capacity Market
- Figure 137. Global Biologics Fermentation Capacity Market Share Analysis, by Key Players (2025)
- Figure 138. Top Five Players: Bioreactor Portfolio and Basis of Position, 2025
- Figure 139. Sartorius AG: Company Snapshot
- Figure 140. Sartorius AG: SWOT Analysis
- Figure 141. Danaher Corporation/Cytiva: Company Snapshot
- Figure 142. Danaher Corporation/Cytiva: SWOT Analysis
- Figure 143. Thermo Fisher Scientific Inc.: Company Snapshot
- Figure 144. Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 145. Merck KGaA: Company Snapshot
- Figure 146. Merck KGaA: SWOT Analysis
- Figure 147. Eppendorf SE: Company Snapshot
- Figure 148. Eppendorf SE: SWOT Analysis
- Figure 149. ABEC, Inc.: Company Snapshot
- Figure 150. ABEC, Inc.: SWOT Analysis
- Figure 151. Getinge AB: Company Snapshot
- Figure 152. Getinge AB: SWOT Analysis
- Figure 153. Tofflon Science and Technology Group Co., Ltd.: Company Snapshot
- Figure 154. Tofflon Science and Technology Group Co., Ltd.: SWOT Analysis
- Figure 155. GEA Group Aktiengesellschaft: Company Snapshot
- Figure 156. GEA Group Aktiengesellschaft: SWOT Analysis
- Figure 157. Pierre Guerin: Company Snapshot
- Figure 158. Pierre Guerin: SWOT Analysis
- Figure 159. ZETA GmbH: Company Snapshot
- Figure 160. ZETA GmbH: SWOT Analysis
- Figure 161. Bioengineering AG: Company Snapshot
- Figure 162. Bioengineering AG: SWOT Analysis
- Figure 163. INFORS HT: Company Snapshot
- Figure 164. INFORS HT: SWOT Analysis
- Figure 165. PBS Biotech, Inc.: Company Snapshot
- Figure 166. PBS Biotech, Inc.: SWOT Analysis
- Figure 167. bbi-biotech GmbH: Company Snapshot
- Figure 168. bbi-biotech GmbH: SWOT Analysis
- Figure 169. Solaris Biotechnology S.r.l.: Company Snapshot
- Figure 170. Solaris Biotechnology S.r.l.: SWOT Analysis
